ADC, Sobi announce EC grants conditional marketing authorization for Zynlonta

ADC Therapeutics and Swedish Orphan Biovitrum announced the European Commission, or EC, has granted conditional marketing authorization for the use of Zynlonta for the treatment of relapsed or refractory diffuse large B-cell lymphoma, or DLBCL. The approval follows an opinion issued in September by the Committee for Medicinal Products for Human Use, or CHMP of the European Medicines Agency, or EMA. Sobi expects to commence launching Zynlonta upon completion of the marketing authorization transfer.